

Supporting information for “Thermosensitive In-situ Hydrogel of Paclitaxel Conjugated Poly(ϵ -caprolactone)-Poly(ethylene glycol)-Poly(ϵ -caprolactone)”

Xiaona Lin, Liandong Deng, Yongshen Xu, Anjie Dong

School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, China




Figure S1 ^1H NMR spectra of PCEC/PTX (A) and NPs released from PCEC/PTX hydrogel (B). CDCl_3 as solvent.





Figure S2 *In vivo* antitumor activity of PCEC/DOX hydrogel against H460 human lung cancer cell-induced Balb/c nude mice. DOX formulations were given by intravenous injection for four doses (days 0, 3, 6, and 9, equivalent to 15 mg/kg of DOX); 100 μL of the 25 wt% aqueous solution of PCEC/DOX (equivalent to 15 mg/kg of DOX) was given by a single intratumoral injection. The relative tumor volume changes as tumor inhibition effect. (n=5)



1 Heart 2 Liver 3 Spleen 4 Lung 5 Kidney 6 Tumor

Figure S3 Systemic distribution of DOX after a single injection of PCEC/DOX (3.75 mg/Kg) hydrogel and a single injection of free DOX (3.75 mg/kg) in xenograft-bearing mice at the 4th day. Drug levels in each tissue (heart, liver, spleen, lung, kidney, tumor) were measured by *in vivo* spectral fluorescence imaging.